Dova Pharmaceuticals (NASDAQ:DOVA) announced its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.12, Fidelity Earnings reports. The firm had revenue of $2.93 million for the quarter, compared to the consensus estimate of $2.66 million.
NASDAQ DOVA traded down $2.41 on Friday, reaching $16.89. The company had a trading volume of 647,924 shares, compared to its average volume of 144,409. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.14 and a current ratio of 13.19. The company has a market cap of $527.66 million, a P/E ratio of -12.06 and a beta of 0.87. Dova Pharmaceuticals has a 12 month low of $16.63 and a 12 month high of $37.00.
In related news, CEO Alex Sapir purchased 21,700 shares of Dova Pharmaceuticals stock in a transaction on Tuesday, August 14th. The shares were bought at an average cost of $22.83 per share, for a total transaction of $495,411.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 55.50% of the company’s stock.
A hedge fund recently raised its stake in Dova Pharmaceuticals stock. Bank of New York Mellon Corp raised its stake in Dova Pharmaceuticals Inc (NASDAQ:DOVA) by 196.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,374 shares of the company’s stock after acquiring an additional 30,750 shares during the period. Bank of New York Mellon Corp owned approximately 0.16% of Dova Pharmaceuticals worth $1,387,000 as of its most recent SEC filing. 36.64% of the stock is currently owned by hedge funds and other institutional investors.
DOVA has been the topic of several recent analyst reports. BidaskClub upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 13th. Leerink Swann reduced their price target on shares of Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, September 4th. Raymond James initiated coverage on shares of Dova Pharmaceuticals in a report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 price target on the stock. Zacks Investment Research upgraded shares of Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, August 15th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target on shares of Dova Pharmaceuticals in a report on Sunday, July 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. Dova Pharmaceuticals has an average rating of “Hold” and a consensus target price of $33.20.
ILLEGAL ACTIVITY WARNING: “Dova Pharmaceuticals (DOVA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/dova-pharmaceuticals-dova-releases-quarterly-earnings-results-beats-expectations-by-0-12-eps.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.
Read More: Should You Consider an Index Fund?
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.